Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)

Inclusion Criteria: * patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C 3.2 mmol/l. * According to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. * The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. * Patient approved to place anonymous results at the disposal of AstraZeneca Exclusion Criteria: * Patients with symptoms of myalgia, myopathy or liver function insufficiency (including raised serum transaminases) which bear a causal relation to the treatment with statins, patients with familiar dyslipidemia and/or patients with contra-indications for treatment with rosuvastatin